Latest Breaking News On - Fruquintinib approval - Page 2 : comparemela.com

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Hong kongRhui zhouUnited statesAdimab incyteMichael shiDaphne zhangAtholl tweedieZhou yiBen atwell alex shawFreddy crossleyEli lillyChina national medical products administrationJournal of the american medical associationChina national reimbursement drug listChina limitedStock exchange of hong kong

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesZhou yiRui hua xuAtholl tweedieDaphne zhangBen atwell alex shawFreddy crossleyChina national reimbursement drug listJournal of the american medical associationAmerican society of clinical oncologyChina limitedExchange commissionStock exchange of hong kongAmerican societyClinical oncology

HUTCHMED Highlights Presentation of Phase III Data on

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13).

United statesHong kongAtholl tweedieBen atwell alex shawDaphne zhangFreddy crossleyZhou yiRui hua xuAmerican society of clinical oncologyChina limitedStock exchange of hong kongExchange commissionChina national reimbursement drug listJournal of the american medical associationAmerican societyClinical oncology

HUTCHMED Highlights Presentation Of Phase III Data On Fruquintinib In Second-Line Gastric Cancer At ASCO Plenary Series Session

HUTCHMED Highlights Presentation Of Phase III Data On Fruquintinib In Second-Line Gastric Cancer At ASCO Plenary Series Session
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesRui hua xuBen atwell alex shawZhou yiPanmure gordonChina limitedChina national reimbursement drug listJournal of the american medical associationStock exchange of hong kongAmerican society of clinical oncologyExchange commissionAmerican societyClinical oncologyPlenary series sessionSeries session

HUTCHMED Receives ELUNATE® (Fruquintinib) Marketing Approval In Hong Kong For Treatment Of Metastatic Colorectal Cancer

HUTCHMED Receives ELUNATE® (Fruquintinib) Marketing Approval In Hong Kong For Treatment Of Metastatic Colorectal Cancer
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesKaren atkinCaron liStephen chanChina national medical products administrationChina national reimbursement drug listDrug administrationJournal of the american medical associationEli lilly companyExchange commissionChina limited nasdaqStock exchange of hong kongPoisons boardHong kong special administrative regionExecutive vice president